Hologic HOLX · NASDAQ
$76.01 +0.00% (+$0.00)
Summary
41 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It could repay all its net debt from 0.6 years of operating profit.
What to watch
- Earnings per share fell by 24% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 30.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
- Analyst estimate
Revenue grew by 1.7% a year over 5 years. Over the last 3 years it grew by 2.2% a year. Earnings per share fell by 24% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 18
- Hold 23
- Sell 1
No analyst has published a price target.
43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.